EQS-Adhoc: SCHOTT Pharma AG & Co. KGaA: SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
|
EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Forecast/Change in Forecast SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
SCHOTT Pharma specifies FY 2025 guidance:
For further information and preliminary Q3/9M 2025 financial results we refer to our supplemental press release. The full set of Q3/9M 2025 financial results will be published on August 12, 2025. Contact Lea Kaiser PR & Communications Manager Tel.: +49 (0) 151 68917195 E-Mail: lea.kaiser@schott.com Tobias Erfurth Head of Investor Relations E-Mail: ir.pharma@schott.com Jasko Terzic, CFA Senior Manager Investor Relations E-Mail: ir.pharma@schott.com End of Inside Information
05-Aug-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | SCHOTT Pharma AG & Co. KGaA |
| Hattenbergstraße 10 | |
| 55122 Mainz | |
| Germany | |
| ISIN: | DE000A3ENQ51 |
| WKN: | A3ENQ5 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2179338 |
| End of Announcement | EQS News Service |
|
|
2179338 05-Aug-2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 584,23 | 648,67 | 821,14 | 898,60 | 957,09 | 986,21 | 1.020,00 | |
| EBITDA1,2 | 131,94 | 164,10 | 219,73 | 239,00 | 257,55 | 280,26 | 274,50 | |
| EBITDA-Margin3 | 22,58 | 25,30 | 26,76 | 26,60 | 26,91 | 28,42 | 26,91 | |
| EBIT1,4 | 98,22 | 127,66 | 164,38 | 192,38 | 192,58 | 200,82 | 198,00 | |
| EBIT-Margin5 | 16,81 | 19,68 | 20,02 | 21,41 | 20,12 | 20,36 | 19,41 | |
| Net Profit (Loss)1 | 77,63 | 101,17 | 125,85 | 151,93 | 150,35 | 146,98 | 145,00 | |
| Net-Margin6 | 13,29 | 15,60 | 15,33 | 16,91 | 15,71 | 14,90 | 14,22 | |
| Cashflow1,7 | 104,40 | 132,21 | 182,12 | 181,65 | 225,33 | 179,92 | 184,00 | |
| Earnings per share8 | 0,51 | 0,67 | 0,83 | 1,01 | 0,99 | 0,97 | 0,95 | |
| Dividend per share8 | 0,00 | 0,00 | 0,12 | 0,15 | 0,18 | 0,18 | 0,18 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Schott Pharma | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3ENQ5 | DE000A3ENQ51 | AG & Co. KGaA | 2.708,05 Mio € | 28.09.2023 | 9F2C268V+9J | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 16,80 | 23,29 | 0,72 | 21,20 | 3,13 | 15,05 | 2,75 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,15 | 0,18 | 0,18 | 1,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 03.02.2026 | 11.02.2026 | 13.05.2026 | 12.08.2026 | 10.12.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +22,22% | +4,01% | +19,07% | -36,01% | -33,41% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
